Becaplermin

Becaplermin
Clinical data
Trade names Regranex
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a699049
Pregnancy
category
  • C
Legal status
  • ℞ (Prescription only)
Routes of
administration		 Topical
Identifiers
CAS Number 165101-51-9 YesY
ATC code A01AD08 , D03AX06
DrugBank DB00102 YesY
ChemSpider none
UNII 1B56C968OA YesY
ChEMBL CHEMBL1201556 N
 NYesY (what is this?)  (verify)

Becaplermin (brand name Regranex) is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. [1]

Use for diabetic foot ulcers has been described.[2] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.[3] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.[4]

The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. [5]

It is also known as "platelet-derived growth factor BB".[6] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [7]

Boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used.[8] Regranex should be used with caution in patients with known malignancy.[9]

References

  1. ↑ http://www.regranex.com/patient/pdf/PI_full_version.pdf.
  2. ↑ Nagai MK, Embil JM (February 2002). "Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers". Expert Opin Biol Ther 2 (2): 211–8. doi:10.1517/14712598.2.2.211. PMID 11849120.
  3. ↑ Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21:822-827.
  4. ↑ Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg. 2002;19:483-491. Persson U, Willis M, Odegaard K, Apelqvist J. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health. 2000;3 Suppl 1:39-46.
  5. ↑ http://www.regranex.com/patient/pdf/PI_full_version.pdf
  6. ↑ becaplermin at the US National Library of Medicine Medical Subject Headings (MeSH)
  7. ↑ Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
  8. ↑ Medscape Article
  9. ↑ http://www.regranex.com/patient/pdf/PI_full_version.pdf

External links

This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.